Abstract
Monoamine transporters are the main targets of methamphetamine (METH). Recently, we showed that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), decreased METH conditioned place preference (CPP), suggesting that serotonin transporter (SERT) inhibition reduces the rewarding effects of METH. To further test this hypothesis, in the present study we investigated the effects of additional SSRIs, paroxetine and fluvoxamine, on METH CPP in C57BL/6J mice. In the CPP test, pretreatment with 20 mg/kg paroxetine abolished the CPP for METH, whereas pretreatment with 100 mg/kg fluvoxamine prior to administration of METH failed to inhibit METH CPP. These results suggest that paroxetine, a medication widely used to treat depression, may be a useful tool for treating METH dependence. Further, these data suggest that molecules other than the SERT [such as G protein-activated inwardly rectifying K+ (GIRK) channels] whose activities are modulated by paroxetine and fluoxetine, but not by fluvoxamine, are involved in reducing METH CPP by paroxetine and fluoxetine.
Keywords: Conditioned place preference, Fluvoxamine, Methamphetamine, Mice, Paroxetine, Serotonin transporter, dopamine transporter, Knoutout mice, Biochemical Down Regulation
Current Neuropharmacology
Title: The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice
Volume: 9 Issue: 1
Author(s): Y. Takamatsu, H. Yamamoto, Y. Hagino, A. Markou and K. Ikeda
Affiliation:
Keywords: Conditioned place preference, Fluvoxamine, Methamphetamine, Mice, Paroxetine, Serotonin transporter, dopamine transporter, Knoutout mice, Biochemical Down Regulation
Abstract: Monoamine transporters are the main targets of methamphetamine (METH). Recently, we showed that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), decreased METH conditioned place preference (CPP), suggesting that serotonin transporter (SERT) inhibition reduces the rewarding effects of METH. To further test this hypothesis, in the present study we investigated the effects of additional SSRIs, paroxetine and fluvoxamine, on METH CPP in C57BL/6J mice. In the CPP test, pretreatment with 20 mg/kg paroxetine abolished the CPP for METH, whereas pretreatment with 100 mg/kg fluvoxamine prior to administration of METH failed to inhibit METH CPP. These results suggest that paroxetine, a medication widely used to treat depression, may be a useful tool for treating METH dependence. Further, these data suggest that molecules other than the SERT [such as G protein-activated inwardly rectifying K+ (GIRK) channels] whose activities are modulated by paroxetine and fluoxetine, but not by fluvoxamine, are involved in reducing METH CPP by paroxetine and fluoxetine.
Export Options
About this article
Cite this article as:
Takamatsu Y., Yamamoto H., Hagino Y., Markou A. and Ikeda K., The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017236
DOI https://dx.doi.org/10.2174/157015911795017236 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Characterization of the Non-Fibrillar α-Synuclein Oligomers
Protein & Peptide Letters Editorial [Hot topic: Melatonin and Brain (Guest Editor: Dun-Xian Tan)]
Current Neuropharmacology Pharmaconutrition with Omega-3 Fatty Acids: Status Quo and Further Perspectives
Mini-Reviews in Medicinal Chemistry Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry Identification of Key mRNAs, miRNAs, and mRNA-miRNA Network Involved in Papillary Thyroid Carcinoma
Current Bioinformatics Long-Term Outcome of Infants Born Late Preterm
Current Pediatric Reviews The Bioinorganic Chemistry of Methimazole Based Soft Scorpionates
Current Bioactive Compounds Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology Diagnosis, Treatment, and New Developments in Preeclampsia
Current Women`s Health Reviews Synthetic Glycolipid Ligands for Human iNKT Cells as Potential Therapeutic Agents for Immunotherapy
Current Medicinal Chemistry Drug Design for Protein Kinases and Phosphatases: Flexible-Receptor Docking, Binding Affinity and Specificity, and Drug-Binding Kinetics
Current Pharmaceutical Design Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock
Current Vascular Pharmacology Parkinson's Disease, Diabetes and Cognitive Impairment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Bariatric Surgery: Indications, Safety and Efficacy
Current Pharmaceutical Design Commentary: Olfactory Dysfunction in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets A Computational Framework to Identify Cross Association Between Complex Disorders by Protein-protein Interaction Network Analysis
Current Bioinformatics Alkylglycerol Lipid Precursors: A Review of Therapeutic Strategies for Plasmalogen Replacement
Current Organic Chemistry HS-MMGKG: A Fast Multi-objective Harmony Search Algorithm for Two-locus Model Detection in GWAS
Current Bioinformatics Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry Potential Applications of Hydrogen Sulfide-Induced Suspended Animation
Current Medicinal Chemistry